{
  "trial_id": "NCT00863746",
  "trial_group": "cancer",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, gender, ECOG Performance Status, histological subtype of NSCLC, number of prior treatment regimens, measurable or non-measurable disease status, hemoglobin level, absolute neutrophil count, platelet count, total bilirubin level, alanine aminotransferase (ALT) level, aspartate aminotransferase (AST) level, alkaline phosphatase level, prothrombin time (PT)-International Normalized Ratio (INR) or partial thromboplastin time (PTT), serum creatinine level, calculated creatinine clearance, life expectancy, ability to swallow oral medication, use of adequate birth control measures.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "gender"
        ],
        [
          "ECOG (Eastern Cooperative Oncology Group) performance status",
          "ECOG Performance Status"
        ],
        [
          "Number of participants with prior anti-cancer therapy and diagnostic procedures",
          "number of prior treatment regimens"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Region (CRF [case report form])",
        "Brain metastasis",
        "Prior EGFR (Epidermal Growth Factor Receptor) inhibitor treatment"
      ],
      "remaining_candidate_features": [
        "histological subtype of NSCLC",
        "measurable or non-measurable disease status",
        "hemoglobin level",
        "absolute neutrophil count",
        "platelet count",
        "total bilirubin level",
        "alanine aminotransferase (ALT) level",
        "aspartate aminotransferase (AST) level",
        "alkaline phosphatase level",
        "prothrombin time (PT)-International Normalized Ratio (INR) or partial thromboplastin time (PTT)",
        "serum creatinine level",
        "calculated creatinine clearance",
        "life expectancy",
        "ability to swallow oral medication",
        "use of adequate birth control measures."
      ]
    },
    "processed-gen-response": "Age, gender, ECOG Performance Status, histological subtype of NSCLC, number of prior treatment regimens, measurable or non-measurable disease status, hemoglobin level, absolute neutrophil count, platelet count, total bilirubin level, alanine aminotransferase (ALT) level, aspartate aminotransferase (AST) level, alkaline phosphatase level, prothrombin time (PT)-International Normalized Ratio (INR) or partial thromboplastin time (PTT), serum creatinine level, calculated creatinine clearance, life expectancy, ability to swallow oral medication, use of adequate birth control measures."
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, ECOG Performance Status, Histological Subtype, Number of Prior Treatment Regimens, Hemoglobin, Absolute Neutrophil Count, Platelet Count, Total Bilirubin, Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase, Prothrombin Time (PT)-International Normalized Ratio (INR), Partial Thromboplastin Time (PTT), Serum Creatinine, Calculated Creatinine Clearance,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Region (CRF [case report form])",
          "Region of Enrollment"
        ],
        [
          "Number of participants with prior anti-cancer therapy and diagnostic procedures",
          "Number of Prior Treatment Regimens"
        ],
        [
          "ECOG (Eastern Cooperative Oncology Group) performance status",
          "ECOG Performance Status"
        ]
      ],
      "remaining_reference_features": [
        "Brain metastasis",
        "Prior EGFR (Epidermal Growth Factor Receptor) inhibitor treatment"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Histological Subtype",
        "Hemoglobin",
        "Absolute Neutrophil Count",
        "Platelet Count",
        "Total Bilirubin",
        "Alanine Aminotransferase (ALT)",
        "Aspartate Aminotransferase (AST)",
        "Alkaline Phosphatase",
        "Prothrombin Time (PT)-International Normalized Ratio (INR)",
        "Partial Thromboplastin Time (PTT)",
        "Serum Creatinine",
        "Calculated Creatinine Clearance"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Region of Enrollment, ECOG Performance Status, Histological Subtype, Number of Prior Treatment Regimens, Hemoglobin, Absolute Neutrophil Count, Platelet Count, Total Bilirubin, Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase, Prothrombin Time (PT)-International Normalized Ratio (INR), Partial Thromboplastin Time (PTT), Serum Creatinine, Calculated Creatinine Clearance"
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, ECOG Performance Status, Prior Systemic Therapy, Number of Prior Systemic Therapies, Best Response to Prior Systemic Therapy, Time Since Last Systemic Therapy, Histology, Disease Stage, Presence of Brain Metastases, Presence of Liver Metastases, Presence of Bone Metastases, Hemoglobin, Absolute Neutrophil Count, Platelet Count, Total Bilirubin, Alanine Aminotransferase, Aspartate Aminotransferase, Alkaline Phosphatase, Prothrombin Time-International Normalized Ratio, Partial Thromboplastin Time, Serum Creatinine, Calculated Creatinine Clearance.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Region (CRF [case report form])",
          "Region of Enrollment"
        ],
        [
          "Number of participants with prior anti-cancer therapy and diagnostic procedures",
          "Number of Prior Systemic Therapies"
        ],
        [
          "Brain metastasis",
          "Presence of Brain Metastases"
        ],
        [
          "ECOG (Eastern Cooperative Oncology Group) performance status",
          "ECOG Performance Status"
        ]
      ],
      "remaining_reference_features": [
        "Prior EGFR (Epidermal Growth Factor Receptor) inhibitor treatment"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Prior Systemic Therapy",
        "Best Response to Prior Systemic Therapy",
        "Time Since Last Systemic Therapy",
        "Histology",
        "Disease Stage",
        "Presence of Liver Metastases",
        "Presence of Bone Metastases",
        "Hemoglobin",
        "Absolute Neutrophil Count",
        "Platelet Count",
        "Total Bilirubin",
        "Alanine Aminotransferase",
        "Aspartate Aminotransferase",
        "Alkaline Phosphatase",
        "Prothrombin Time-International Normalized Ratio",
        "Partial Thromboplastin Time",
        "Serum Creatinine",
        "Calculated Creatinine Clearance"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Region of Enrollment, ECOG Performance Status, Prior Systemic Therapy, Number of Prior Systemic Therapies, Best Response to Prior Systemic Therapy, Time Since Last Systemic Therapy, Histology, Disease Stage, Presence of Brain Metastases, Presence of Liver Metastases, Presence of Bone Metastases, Hemoglobin, Absolute Neutrophil Count, Platelet Count, Total Bilirubin, Alanine Aminotransferase, Aspartate Aminotransferase, Alkaline Phosphatase, Prothrombin Time-International Normalized Ratio, Partial Thromboplastin Time, Serum Creatinine, Calculated Creatinine Clearance."
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, ECOG performance status, histology, number of prior treatment regimens, presence of measurable or non-measurable disease, life expectancy, hemoglobin, absolute neutrophil count, platelet count, total bilirubin, ALT, AST, alkaline phosphatase, prothrombin time-INR or PTT, serum creatinine, calculated creatinine clearance.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "ECOG (Eastern Cooperative Oncology Group) performance status",
          "ECOG performance status"
        ],
        [
          "Number of participants with prior anti-cancer therapy and diagnostic procedures",
          "number of prior treatment regimens"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Region (CRF [case report form])",
        "Brain metastasis",
        "Prior EGFR (Epidermal Growth Factor Receptor) inhibitor treatment"
      ],
      "remaining_candidate_features": [
        "histology",
        "presence of measurable or non-measurable disease",
        "life expectancy",
        "hemoglobin",
        "absolute neutrophil count",
        "platelet count",
        "total bilirubin",
        "ALT",
        "AST",
        "alkaline phosphatase",
        "prothrombin time-INR or PTT",
        "serum creatinine",
        "calculated creatinine clearance"
      ]
    },
    "processed-gen-response": "Age, sex, ECOG performance status, histology, number of prior treatment regimens, presence of measurable or non-measurable disease, life expectancy, hemoglobin, absolute neutrophil count, platelet count, total bilirubin, ALT, AST, alkaline phosphatase, prothrombin time-INR or PTT, serum creatinine, calculated creatinine clearance."
  }
}